TACE联合胸腺肽α1治疗不可切除性肝细胞肝癌

Trascatheter arterial chemoembolization combined with thymosin α1 for unresectable hepatocellular carcinoma

目的评估经动脉化疗栓塞(trascatheter arterial chemoembolization,TACE)联合胸腺肽α1(α1)治疗不可切除性肝细胞肝癌(HCC)的疗效。方法将64例不可切除性HCC患者分成2组,TACE+Tα1治疗组32例,予TACE治疗后每2天皮下注射1.6 mg Tα1,持续24周;单纯TACE治疗组32例,术后予对症支持治疗。通过肿瘤反应、疾病进展时间评估疗效。结果 TACE+Tα1组:肿瘤反应率62.5%、中位疾病进展时间31周;单纯TACE组:肿瘤反应率46.9%、中位疾病进展时间19周,两组比较肿瘤反应率差异无统计学意义(P=0.209),中位疾病进展时间差异有统计学意义(P=0.03)。结论TACE联合Tα1治疗不可切除性HCC可延长中位疾病进展时间,提高患者生活质量,但肿瘤反应率未见改善。

Objective To evaluate the efficacy of unreseetable hepatocellular carcinoma （ HCC ） treated with transcatheter arterial chemoembolization （trascatheter arterial chemoembolization, TACE） and thymosin α1 （ Tαl ）. Methods 64 cases of unreseetable HCC patients was divided into two groups. 32 cases enter TACE ＋ Tα1 group, underwent TACE and treatment of Tα1 1.6 mg subcutaneous injection every 2 days, continue for 24 weeks; 32 cases underwent TACE only with symptomatic supportive care. We assess the efficacy through the tumor response and time toprogression. Results TACE ＋Tα1 group： tumor response rate is 62.5 % and median time toprogression is 31 weeks, TACE group tumor response rate is 46.9%, median time toprogression is 19 weeks, there is no statistically significant difference in tumor response rate betwent two groups （ P = 0. 209 ）, there is statistically significant difference in median time toprogression betwent two groups （ P = 0.03 ）. Conclusions The treatment of TACE combined Tα1 can extend median time to progression and improve quality of life for unresectable HCC patient, but there is no inprovement in tumor response rate.